Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.67 |
| ▸ | PKM | P14618 | 2/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.67 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6313762 | 0.99 | KDM4E (0.65) | KDM4EPKMADORA2ALMNAADORA3 | |
| SCHEMBL6319598 | 0.89 | KDM4E (0.51) | KDM4EPKMADORA2ALMNAADORA3 | |
| SCHEMBL6321413 | 0.87 | KDM4E (0.50) | KDM4EPKMADORA2ALMNAADORA3 | |
| SCHEMBL6318412 | 0.86 | PKM (0.49) | KDM4EPKMADORA2ALMNAADORA3 | |
| SCHEMBL6319215 | 0.86 | PKM (0.66) | KDM4EPKMADORA2ALMNAADORA3 | |
| SCHEMBL6259451 | 0.85 | PKM (0.48) | KDM4EPKMADORA2ALMNAADORA3 | |
| SCHEMBL3709038 | 0.84 | PKM (0.47) | KDM4EPKMADORA2ALMNAADORA3 | |
| Hydrochloric Acid SCHEMBL6313034 | 0.84 | PKM (0.47) | KDM4EPKMADORA2ALMNAADORA3 | |
| Hydrochloric Acid SCHEMBL6313060 | 0.84 | KDM4E (0.47) | KDM4EPKMADORA2ALMNAADORA3 | |
| Hydrochloric Acid SCHEMBL6313310 | 0.83 | ALDH1A1 (0.54) | KDM4EPKMADORA2ALMNAADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6941051-B2 | Method for producing non-linear optical organic crystal film | REVEO, INC. (US) | 2005-09-06 | — | — | US | claimed |
| EP-1499317-A1 | TREATMENT OF DIABETES AND DIABETIC COMPLICATIONS WITH NHE-1 INHIBITORS | Pfizer Products Inc. (US) | 2005-01-26 | — | — | EP | claimed |
| US-20040033038-A1 | Method for producing non-linear optical organic crystal film | XU JIANJUN (US) | 2004-02-19 | — | — | US | claimed |
| WO-2003092694-A1 | TREATMENT OF DIABETES AND DIABETIC COMPLICATIONS WITH NHE-1 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-11-13 | — | — | WO | claimed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | claimed |
| US-6577798-B2 | Method for producing non-linear optical organic crystal film | REVEO, INC. | 2003-06-10 | — | — | US | claimed |
| CN-1370531-A | Combined therapy | PFIZER PRODUCT CO (US) | 2002-09-25 | — | — | CN | claimed |
| EP-1226830-A2 | Combination therapy involving a sodium-hydrogen exchanger type 1 or NHE-1 inhibitor for use in treatment of ischemia | Pfizer Products Inc. (US) | 2002-07-31 | — | — | EP | claimed |
| US-20020099075-A1 | COMBINATION THERAPY | TRACEY WAYNE R (US) | 2002-07-25 | — | — | US | claimed |
| US-6423705-B1 | FOR ISCHEMIA BY ADMINISTERING AN NHE-1 INHIBITOR AND A SECOND COMPOUND SELECTED FROM COMPLEMENT MODULATOR, METABOLIC MODULATOR, ANTIAPOPTOTIC AGENT, NITRIC OXIDE SYNTHASE-RELATED AGENT, AND AN ENZYME/PROTEIN MODULATOR | PFIZER INC. | 2002-07-23 | — | — | US | claimed |
| US-20020041427-A1 | Method for producing non-linear optical organic crystal film | REVEO, INC. | 2002-04-11 | — | — | US | claimed |
| WO-2002008828-A2 | COMPOSITE NONLINEAR OPTICAL FILM, METHOD OF PRODUCING THE SAME AND APPLICATIONS OF THE SAME | REVEO, INC. (US) | 2002-01-31 | — | — | WO | claimed |
| WO-2002006890-A2 | METHOD FOR PRODUCING NON-LINEAR OPTICAL ORGANIC CRYSTAL FILM | REVEO, INC. (US) | 2002-01-24 | — | — | WO | claimed |
| US-6303056-B1 | Composite nonlinear optical film, method of producing the same and applications of the same | REVEO, INC. | 2001-10-16 | — | — | US | claimed |
| CN-1289326-A | N-[(substituted five-membered di-or thiaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER PROD INC (US) | 2001-03-28 | — | — | CN | claimed |
| EP-1056729-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2000-12-06 | — | — | EP | claimed |
| WO-1999043663-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 1999-09-02 | — | — | WO | claimed |
| WO-2015189236-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING CD95-MEDIATED CELL MOTILITY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-12-17 | — | — | WO | disclosed |
| EP-1056729-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999043663-A1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | KDM4E 3920/4885PKM 3050/4885ADORA2A 999/4885 |
| US-20020099075-A1 | COMBINATION THERAPY | TFPI, SLC9A1, TFPI2 | KDM4E 4327/4885PKM 1086/4885ADORA2A 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.